

## Clinical Laboratory Division and Diagnostic Pathology Division

1. Shibata T, Watanabe H, Tsurusaki T, Minai K, Ogawa T, Iwano K, Tamura T, Yoshida S, Mutou M, Imai K, Horie H, Mochizuki S. Do indices of coronary conductance after reperfusion reflect the extent of salvaged myocardium? *Jpn Heart J* 2004; 45: 387-396.
2. Nakagawa T, Kanai Y, Fujimoto H, Kitamura H, Furukawa H, Maeda S, Oyama T, Takesaki T, Hasegawa T. Malignant mixed epithelial and stromal tumours of the kidney: a report of the first two cases with a fatal clinical outcome. *Histopathol* 2004; 44: 302-304.
3. Yamaguchi U, Hasegawa T, Masuda T, Sekine S, Kawai A, Chuman H, Shimoda T. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. *Virchows Arch* 2004; 445: 142-150.
4. Okada K, Hasegawa T, Tateishi U, Itoi E. Second primary osteosarcoma with rosette-like structures in a patient with retinoblastoma. *Virchows Arch* 2004; 445: 421-424.
5. Sakurai S, Hasegawa T, Sakuma Y, Takazawa Y, Motegi A, Nakajima T, Saito K, Fukayama M, Shimoda S. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. *Hum Pathol* 2004; 35: 1223-1230.
6. Yamada H, Ikegami M, Shimoda T, Takagi N, Maruyama M. Long-term follow-up study of gastric adenoma/dysplasia. *Endoscopy* 2004; 36: 390-396.
7. Yachida S, Nakanishi Y, Shimoda T, Nimura S, Igaki H, Tachimori Y, Kato H. Adenosquamous carcinoma of the esophagus. *Oncology* 2004; 66: 218-225.
8. Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, Kumamoto T, Ishiguro S, Kati Y, Shimoda T, Iwashita A, Ajioka Y, Watanabe H, Watanabe T, Muto T, Nagasako K. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. *J Gastroenterol* 2004; 39: 534-543.
9. Sekine S, Shimoda T, Nimura S, Nakanishi N, Akasu T, Katai H, Gotoda T, Shibata T, Sakamoto M, Hirohashi S. High-grade dysplasia associated with fundic gland polyposis in a familial adenomatous polyposis patient, with special reference to APC mutation profiles. *Mod Pathol* 2004; 17: 1421-1426.
10. Oikawa T, Ojima H, Yamasaki S, Takayama T, Hirohashi S, Sakamoto M. Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules. *J Hepatol* 2005; 42: 225-229.
11. Hammar SP, Brambilla C, Pugatch B, Geisinger K, Fernandez EA, Vogt P, Petrovitchev N, Matsuno Y, Aisner S, Rami-Porta R, Capelozzi VL, Schmidt R, Carvalho L, Petersen I, Gazdar A, Meyerson M, Hanash SM, Jen J, Harris CC. Squamous cell carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. *World Health Organization Classification of Tumours, Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart*. Lyon: IARC Press 2004; 26-30.
12. Colby TV, Noguchi M, Henschke C, Vazquez MF, Geisinger K, Yokose T, Ohori P, Rami-Porta R, Franks T, Shimosato Y, Matsuno Y, Khor A, Westra WH, Jambhekar NA, Petersen I, Takahashi T, Kawai T, Meyerson M, Hanash SM, Jen J. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. *World Health Organization Classification of Tumours, Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart*. Lyon: IARC Press 2004; 35-44.
13. Matsuno Y, Rosai J, Shimosato Y. Papillary adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. *World Health Organization Classification of Tumours, Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart*. Lyon: IARC Press 2004; 183.
14. Hasegawa T. Solitary fibrous tumour, tumours of the kidney. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. *World Health Organization Classification of Tumours, Pathology and Genetics of the Tumours of the Urinary System and Male Genital Organs*. Lyon: IARC Press 2004; 75.
15. Tominaga K, Nakanishi Y, Nimura S, Yoshimura K, Sakai Y, Shimoda T. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma. *Dis Colon Rectum* (in press).
16. Okada K, Hasegawa T, Nishida J, Ogoe A, Tajino T, Osanai T, Yanagisawa M, Hatori M. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases. An experience in Northern Japan. *Ann Surg Oncol* (in press).
17. Ojima H, Hasegawa T, Matsuno Y, Sakamoto M. Extramedullary myeloid tumor (EMMT) of the gallbladder. *J Clin Pathol* (in press).
18. Tashiro T, Hasegawa T, Omatsu M, Sekine S, Shimoda T, Katai H. Gastrointestinal stromal tumor of the stomach showing lymph node metastases. *Histopathol* (in press).
19. Yamaguchi U, Hasegawa T, Sakurai S, Sakuma Y, Takazawa Y, Hishima T, Mitsuhashi T, Sekine S, Chuman H, Shimoda T. Interobserver variability in histologic recognition, interpretation of KIT immunostaining and determining MIB-1 labeling indices in gastrointestinal stromal tumors and other spindle cell tumors of the gastrointestinal tract. *Appl Immunohistochem Mol Morphol* (in press).
20. Takahashi F, Tsuta K, Matsuno Y, Takahashi K, Toba M, Sato K, Uekusa T, Izumi H, Nakamura K, Hirose S, Fukuchi Y. Adenocarcinoma of the thymus: mucinous subtype. *Hum Pathol* (in press).

## Diagnostic Radiology Division

21. Takayasu K, Muramatsu Y, Mizuguchi Y, Moriyama N, Ojima H. Imaging of early hepatocellular carcinoma and adenomatous hyperplasia (dysplastic nodule) on dynamic CT and combination of CT and angiography: experience in resected liver specimen. *Intervirology* 2004; 47: 199-208.
22. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K, Yamaoka Y, The Liver Cancer Study Group of Japan. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. *Cancer* 2004; 101: 796-802.
23. Oshiro Y, Kusumoto M, Matsuno Y, Asamura H, Tsuchiya R, Terasaki H, Takei H, Maeshima A, Murayama S, Moriyama N. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. *Am J Roentgenol*. 2004; 182: 87-91.

24. Tateishi U, Hasegawa T, Beppu Y, Kawai A, Satake M, Moriyama N. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. *Am J Roentgenol*. 2004; 182: 725-731.
25. Tateishi U, Hasegawa T, Beppu Y, Satake M, Moriyama N. Synovial sarcoma of the soft tissues: prognostic significance of imaging features. *J Comput Assist Tomogr*. 2004; 28: 140-148.
26. Tateishi U, Muller NL, Johkoh T, Onishi Y, Arai Y, Satake M, Matsuno Y, Tobinai K. Primary mediastinal lymphoma: characteristic features of the various histological subtypes on CT. *J Comput Assist Tomogr*. 2004; 28: 782-789.
27. Takayasu K, Muramatsu Y, Mizuguchi Y, Moriyama N, Okusaka T. Multiple non-tumorous arterioportal shunts due to chronic liver disease mimicking hepatocellular carcinoma: outcomes and the associated elevation of alpha-fetoprotein. *Journal of Gastroenterology and Hepatology*. (in press)
28. Tateishi U, Hasegawa T, Onaya H, Satake M, Arai Y, Moriyama N. Myxoinflammatory Fibroblastic Sarcoma: MR Appearance and Pathologic Correlations. *Am J Roentgenol* (in press)

### Endoscopy Division

29. Yamasaki R, Yokota K, Okada H, Hayashi S, Mizuno M, Yoshino T, Hirai Y, Saito D, Akagi T, Oguma K. Immune response in helicobacter pylori-induced low-grade gastric-mucosa-associated lymphoid tissue(MALT) lymphoma. *Journal of Medical Microbiology* 2004; 53: 21-29.
30. Gotoda T. Endoscopic diagnosis and treatment for early gastric cancer. *Cancer Reviews* 2004; 2: 17-37.
31. Saito Y, Emura F, Matsuda T, Saito D, Fujii T. Letter to the editor: Invasive pattern is an indication for surgical treatment. *Gut on line*. 2004.
32. Saito Y, Matsuda T, Saito D, Fujii T, Emura F, Sano Y. Does endoscopic resection increase the risk of lymph node metastases? *Gastrointestinal Endoscopy* 2004; 59(5): AB274.
33. Saito Y, Nakajima T, Uraoka T, Emura F, Matsuda T, Gotoda T, Oda I, Ikematsu H, Kobayashi N, Saito D. *Endoscopy* 2004; 36(1): A267.
34. Matsuda T, Fujii T, Emura F, Kozu T, Saito Y, Ikematsu H, Saito D. Complete closure of a large defect after EMR of a lateral spreading colorectal tumor when using a two-channel colonoscope. *Gastrointest Endosc* 2004; 60: 836-38
35. Matsuda T, Fujii T, Emura F, Kozu T, Saito Y, Ikematsu H, Saito D. Complete closure of a large defect after EMR of a colorectal tumor using a two-channel colonoscope. *GI Endoscopy* (in press)
36. Oda I, Gotoda T, Hamanaka H, Eguchi T, Saito Y, Matsuda T, Bhandari P, Emura F, Saito D and Ono H. Endoscopic submucosal dissection for early gastric cancer: Technical feasibility, operation time and complications from a large consecutive series. *Digestive Endoscopy* (in press)
37. Sano Y, Saito Y, Kuang-I Fu, Matsuda T, Uraoka T, Kobayashi N, Ito H, Machida H, Emura F, Hanahusa M, Iwasaki J, Yoshino T, Kato S, Fuji T. <Review: How I do it> Efficacy of Magnifying Chromoendoscopy for the Differential Diagnosis of Colorectal Lesions. *Digestive Endoscopy* (in press)
38. Saito Y, Taniguchi M, Tagawa T, Ibukuro K, Mori M, Emura F. A case of phlebosclerotic colitis with deep circumferential ulceration: Three-year endoscopic follow-up. *Dis Colon Rectum* (in press)

### Breast and Medical Oncology Division

39. Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N, Fujiwara Y. Expression of Insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. *Human Pathol* 2004; 35: 1537-1542
40. Yonemori K, Katsumata N, Uno H, Matsumoto K, Kouno T, Tokunaga S, Yamanaka Y, Shimizu C, Ando M, Takeuchi M, Fujiwara Y. *Breast Cancer Res Treat* (in press)

### Gastrointestinal Oncology Division

41. Matsumura Y, Goto M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K and Takahashi K. Phase I and Pharmacokinetic study of MCC-465 of doxorubicin(DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. *Annals of Oncology* 2004; 15: 517-525.
42. Shirao K, Ohtsu S, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh S. Phase II study of oral S-1 for metastatic colorectal cancer. *CANCER* 2004; 100: 2355-2361.
43. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W and Ohtsu T. A Phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. *Annals of Oncology* 2004; 15: 955-959.
44. Sai K, Saeki M, Saito Y, Ozawa S, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu S, Shirao K, Yoshida T and Saijo N. UGT1A1 Haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. *Clinical Pharmacology & Therapeutics* 2004; 75(6): 501-515.
45. Shirao K, P. M. Hoff, A. Ohtsu, P. J. Loehrer, Hyodo I, S. Wadler, R.G. Wadleigh, P. J. O'Dwyer, Muro K, Yamada Y, Boku N, Nagashima F, J. L. Abbruzzese. Comparison of the Efficacy, Toxicity, and Pharmacokinetics of a Uracil/tegafur plus Oral Leucovorin Regimen between Japanese and American Patients with Advanced Colorectal Cancer: Joint USA and Japan Study of UFT / LV. *J Clin Oncol* 2004; 22(17): 3466-3474.
46. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, Saito H, Iwase H, Tsuji Y, Tamura T, Yamamoto S and Yoshida S. Phase I/II study of Sequential Methotrexate and 5-Fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the gastrointestinal oncology study group of the Japan Clinical Oncology Group, JCOG 9603 trial. *Jpn J Clin Oncol* 2004; 34(6): 316-322.
47. Fukushima-Uesaka H, Sai K, Maekawa K, Koyano S, Kaniwa N, Ozawa S, Kawamoto M, Kamatani N, Komamura K, Kamakura S, Kitakaze M, Tomoike H, Ueno K, Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N, Saito Y and Sawada J. Genetic Variations of the AHR Gene Encoding Aryl Hydrocarbon Receptor in a Japanese Population. *Drug Metabol Pharmacokin* 2004; 19(4): 320-326.

48. Hosokawa A, Shimada Y, Shirao K, Matsumura Y, Yamada Y, Muro K, Hamaguchi T, Goto M and Shimoda T. Long-term survivor of gastric small cell carcinoma. *Hepato-Gastroenterology* 2004; 51: 1567-1570.
49. Hamaguchi T, Matsumura Y, Nakanishi Y, Muro K, Yamada Y, Shimada Y, Shirao K, Niki H, Hosokawa S, Tagawa T and Kakizoe T. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. *Cancer Sci* 2004; 95(7): 608-613.
50. Goto A, Yamada Y, Hosokawa A, Ura T, Arai T, Hamaguchi T, Muro K, Shimada Y and Shirao K. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. *Int J Clin Oncol* 2004; 9: 364-368.
51. Hosokawa A, Yamada Y, Shimada Y, Muro K, Hamaguchi T, Morita H, Araake M, Orita H and Shirao K. Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. *Int J Clin Oncol* 2004; 9: 388-392.
52. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M and Watanabe N. Phase I clinical trial pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. *British Journal of Cancer*. 91: 1775-1781, 2004.
53. Yonemori K, Shimada S, Goto A, Ura T, Arai T, Hamaguchi T, Muro K, Yamada Y, Shirao K. Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy. *Gastric Cancer* 2004; 7: 204-210.
54. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, Hyodo I, Koizumi W, Kurihara M, Yoshida S and Yamamoto S. Long-term Survival and Prognostic Factors in Patients with Metastatic Gastric Cancers Treated with Chemotherapy in the Japan Clinical Oncology Group (JCOG) Study. *Jpn J Clin Oncol* 34(11): 654-659, 2004.
55. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S and Sawada J. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. *HUMAN MUTATION* Mutation in Brief (in press)
58. Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita K, Hiraoka A, Matsuno Y, Nakamura S, Mori S, Ohashi Y. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. *Ann Oncol* 2004; 15: 821-830.
59. Sekiguchi N, Nishimoto J, Tanosaki R, Kobayashi Y, Watanabe T, Kami M, Mineishi S, Takaue Y, Matsuno Y and Tobinai K. EBV-positive Burkitt lymphoma as a late-onset post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation. *Int J Hematol* 2004; 79: 387-389.
60. Armitage JO, Tobinai K, Hoelzer D, Rummel MJ. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. *Int J Hematol* 2004; 79: 311-321.
61. Kusumoto S, Kobayashi Y, Tanimoto TE, Hasegawa T, Tanimoto K, Sekiguchi N, Narabayashi M, Watanabe T, Matsuno Y, Tobinai K. T(11; 18)-bearing pulmonary MALT lymphoma responding to cladribine. *Int J Hematol* 2004; 80: 70-74.
62. Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Ishizuka N, Tomonaga M, Sai T, Ohno Y, Kasai M, Ogura M, Mikuni C, Toki H, Sano M, Masaki Y, Niimi M, Matsuno Y, Takenaka T, Shirakawa S, Shimoyama M. A randomized controlled trial investigating survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. *Int J Hematol* 2004; 80: 341-350.
63. Takenaka T, Itoh K, Suzuki T, Utsunomiya A, Matsuda S, Chou T, Sai T, Sano M, Konda S, Ohno T, Mikuni C, Deura K, Yamada T, Mizorogi F, Nagoshi H, Tomonaga M, Hotta T, Kawano K, Tsushita K, Hirano M, Shimoyama M. Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan Clinical Oncology Group study, JCOG 9301. *Int J Hematol* 2004; 79: 165-173.
64. Tobinai K, Hotta T. Clinical trials for malignant lymphoma in Japan. *Jpn J Clin Oncol* 2004; 34: 369-378.
65. Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Cho K, Kasai M, Murayama T, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K. Durable response but prolonged cytopenia and myelodysplastic syndrome after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: Results of a Japanese phase II study. *Int J Hematol* 2004; 80: 267-277.
66. Tobinai K, Watanabe T, Jaffe ES. Human T-cell leukemia virus type I-associated adult T-cell leukemia-lymphoma. In: Mauch PM, Armitage JO, Harris NL, Coiffier B, Dalla-Favera R, editors. *Non-Hodgkin's Lymphomas*. Philadelphia: Lippincott Williams & Wilkins 2004; 295-305.
67. Tobinai K, Watanabe T: Adult T-cell leukemia-lymphoma. In: Abeloff MD, Armitage JO, Kastan M, Niederhuber JE, editors. *Clinical Oncology*, 3rd edition. Philadelphia: W.B. Saunders, Elsevier Science 2004; 3109-3130.
68. Sekiguchi N, Kobayashi Y, Yokota Y, Kusumoto S, Watanabe T, Matsuno Y, Tobinai K. Follicular lymphoma sub-grouping by fluorescence in situ hybridization (FISH) analysis. *Cancer Sci*, (in press).
69. Kouno T, Watanabe T, Umeda T, Beppu Y, Kojima R, Kobayashi Y, Tobinai K, Hasegawa T, Matsuno Y. Osseous plasmacytoma presenting in which CD56 detection was a key to definitive diagnosis. *Jpn J Clin Oncol*, (in press).

## Hematopoietic Stem Cell Transplantation Team

70. Hori A, Kami M, Kim SW, Murashige N, Sakiyama M, Kojima R, Hamaki T, Makimoto A, Miyakoshi S, Masuo S, Taniguchi S, Kunitoh H, Takaue Y. Urgent need for a validated tumor response evaluation system for use in immunotherapy. *Bone Marrow Transplant* 2004; 33: 255-256.
71. Kawano Y, Chan LL, Watanabe T, Abe T, Okamoto Y, Makimoto A, Nakagawa R, Watanabe H, Suzuya H, Takaue Y. Cryopreservation of mobilized blood stem cells at a higher cell concentration without the use of a programmed freezer. *Ann Hematology* 2004; 83: 50-54.
72. Yamasaki S, Ohno Y, Taniguchi S, Yoshida T, Hayashi S, Ogawa H, Shimazaki C, Takahashi S, Kasai M, Wake A, Nishimura M, Tokunaga K, Gondo H, Takaue Y, Harada M, Mineishi S. Allogeneic peripheral blood stem cell transplantation from 2- or 3-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies. *Bone Marrow Transplant* 2004; 33: 279-289.
73. Kamitsuji Y, Mori S, Kami M, Yamada H, Shirakawa K, Kishi Y, Murashige N, Kim SW, Heike Y, Takaue Y. Fatal deep vein thrombosis after allogeneic reduced-intensity hematopoietic stem-cell transplantation for the treatment of metastatic gastric cancer. *Ann Hematol* 2004; 83: 533-535.
74. Harashima N, Kurihara K, Utunomiya A, Tanosaki R, Hanabuchi S, Masuda M, Ohashi T, Fukui F, Hasegawa A, Masuda T, Takaue Y, Okamura J, Kannagi M. Graft-versus-human T-cell leukemia virus type-I response in adult T-cell leukemia patients following non-myeloablative hematopoietic stem cell transplantation. *Cancer Res* 2004; 64: 391-399.
75. Hori A, Kami M, Kim SW, Chizuka A, Kojima R, Imataki O, Sakiyama M, Hamaki T, Onishi Y, Usubuchi N, Kishi Y, Murashige N, Tajima K, Miyakoshi S, Heike Y, Masuo S, Taniguchi S, Takaue Y. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. *Biol Blood Marrow Transplant* 2004; 10: 65-72.
76. Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y, Gondo H, Harada M, Sakamaki H, Yajima T, Iwao Y, Hibi T, Okamoto S. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2004; 33: 431-434.
77. Tanimoto TE, Saito A, Tanaka Y, Yamaguchi T, Tajima K, Karasuno T, Kasai M, Kishi K, Mori T, Maseki N, Morishima S, Miyakoshi S, Yamashita T, Ohno Y, Kim SW, Numata A, Kami M, Takaue Y, Mori S, Harada M. Graft-versus-host disease and clinical outcomes after allogeneic hematopoietic stem cell transplantation with bone marrow or blood stem cells. *Br J Haematol* 2004; 125: 480-493.
78. Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Kim SW, Heike Y, Ueyama J, Miyakoshi S, Tanosaki R, Morinaga S, Mineishi S, Muto Y, Takaue Y. Feasibility of reduced-intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. *Bone Marrow Transplant* 2004; 33: 697-702.
79. Imataki O, Kim SW, Kami M, Gotoh M, Komaba S, Kasai M, S Hashino S, Naito K, Masuda M, Anan K, Teshima H, Togitani K, Inoue T, Nishimura M, Adachi Y, Fukuhara T, Yamashita T, Uike N, Kobayashi Y, Hamaguchi M, Higuchi M, Kawakami K, Takaue Y. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2004; 33: 1173-1179.
80. Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, Kishi Y, Fujimoto H, Matsuoka N, Okajima E, Komiyama M, Tobisu K, Wakayama T, Uike N, Tajima K, Makimoto A, Mori S, Tanosaki R, Takaue Y, Kakizoe T. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for the treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. *Exp Hematol* 2004; 32: 599-606.
81. Kishi Y, Miyakoshi S, Kami M, Ikeda M, Katayama Y, Murashige N, Kusumi E, Yuji K, Kobayashi K, Kato D, Hamaki T, Matsumura T, Kim SW, Morinaga S, Mori S, Kanemaru N, Hayashi T, Takaue Y, Taniguchi S. Early central nervous system complications after reduced-intensity stem cell transplantation. *Biol Blood Marrow Transplant* 2004; 10: 561-568.
82. Kojima R, Kami M, Nannya Y, Kusumi E, Sakai M, Tanaka Y, Kanda Y, Mori S, Chiba S, Miyakoshi S, Tajima K, Hirai H, Taniguchi S, Sakamaki H, Takaue Y. Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. *Biol Blood Marrow Transplant* 2004; 10: 645-652.
83. Sakiyama M, Kami M, Hori A, Imataki O, Hamaki T, Murashige N, Kobayashi K, Kishi Y, Kojima R, Kim SW, Kusumi E, Yuji K, Miyakoshi S, Mori S, Tanosaki R, Taniguchi S, Takaue Y. Regimen-related toxicity following reduced-intensity stem-cell transplantation: comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0. *Bone Marrow Transplant* 2004; 34: 787-794.
84. Kannagi M, Harashima N, Kurihara K, Utunomiya A, Tanosaki R, Masuda M. Adult T-cell leukemia: future prophylaxis and immunotherapy. *Expert Rev Anticancer Ther* 2004; 4: 369-376.
85. Sekiguchi N, Nishimoto J, Tanosaki R, Kubota N, Yokota Y, Kobayashi Y, Watanabe T, Kami M, Takaue Y, Matsuno Y, Tobinai K. EBV-positive Burkitt lymphoma as a late-onset posttransplantation lymphoproliferative disorder after allogeneic stem cell transplantation. *Int J Hematol* 2004; 79: 387-389.
86. Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N, Hiraoka A, Kanda Y, Tanosaki R, Okamoto S, Iwato K, Atsuta Y, Hamajima N, Tanimoto M, Kato S. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. *Bone Marrow Transplant* 2004; 34: 331-337.
87. Kojima R, Kami M, Hori A, Murashige N, Ohnishi M, Kim SW, Hamaki T, Kishi Y, Tsutsumi Y, Masauzi N, Heike Y, Mori S, Kobayashi K, Masuo S, Tanosaki R, Takaue Y. Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer. *Transplantation* 2004; 78: 1740-1746.
88. Kami M, Hori A, Takaue Y, Mutou Y. Gastrointestinal tract is a common target of invasive aspergillosis in patients receiving cytotoxic chemotherapy for hematological malignancy. *Clin Inf Dis* (in press)

89. Hamaki T, Kami M, Momomura SI, Mineishi S, Kusumi E, Kanda Y, Ueyama JI, Miyakoshi S, Morinaga SI, Takaue Y, Mutou Y. Sustained molecular remission in a patient with CML in blastic crisis receiving dose-reduced hematopoietic stem-cell transplantation followed by early withdrawal of cyclosporine and prophylactic use of interferon-alpha. *Am J Hematol* (in press)
90. Hori S, Takei M, Heike Y, Maruyama M, Inoue Y, Lee YJ, Kim HJ, Harada Y, Kawai H, Shimosaka A, Kami M, Tanosaki R, Kato K, Wakasugi H, Saito S, Takaue Y, Kakizoe T. Freeze-thawing procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14+ monocytes. *J Immunother* (in press)
91. Hamaki T, Kami M, Kim SW, Onishi Y, Kishi Y, Murashige N, Hori A, Kojima R, Sakiyama M, Imataki O, Heike Y, Tanosaki R, Masuo S, Miyakoshi S, Taniguchi S, Tobinai K, Takaue Y. Reduced-intensity stem-cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. *Bone Marrow Transplant* (in press)
92. Hori A, Kami M, Kim SW, Kojima R, Urahama N, Imataki O, Murashige N, Makimoto A, Kanda Y, Heike Y, Tanosaki R, Mineishi S, Takaue Y. Balance between acute graft-versus-host disease and graft-versus-tumor effect after reduced-intensity transplantation for metastatic renal cell carcinoma: Report of two cases. *Hematology Journal* (in press)
93. Hori A, Kanda Y, Goyama S, Onishi Y, Komeno Y, Mitani K, Kishi Y, Ogawa S, Imataki O, Chiba S, Kojima R, Hamaki T, Sakiyama M, Kami M, Makimoto A, Tanosaki R, Takaue Y, Hirai H, for the Japan Hematology and Oncology Clinical Study Group (J-HOCS). A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. *Transplantation* (in press)

### Hepatobiliary and Pancreatic Oncology Division

94. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kudo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. *Invest New Drug* 2004; 22: 169-176.
95. Okusaka T, Kosuge T. Systemic chemotherapy for pancreatic cancer. *Pancreas* 2004; 28: 301-304.
96. Okusaka T, Matsumura Y, Aoki K. New approach for pancreatic cancer in Japan. *Cancer Chemother Pharmacol* 2004; 54: S78-S82.
97. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Ikeda H. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. *Br J Cancer* 2004; 91: 673-677.
98. Ueno H, Okusaka T, Ikeda M, Tokuyue K. Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer. *Oncology* 67: 215-221, 2004.
99. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. A phase II study of S-1 in patients with advanced biliary tract cancer. *Br J Cancer* 91: 1769-1774, 2004.
100. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. *Oncology* (in press).

101. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone and cisplatin for metastatic hepatocellular carcinoma. *Cancer* (in press).
102. Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, Fujiyama S, Tomita K. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. *Oncology* (in press).
103. Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H. Risk factor of hepatocellular carcinoma after sustained response to interferon in patients with chronic hepatitis C. *J Gastroenterol* (in press).
104. Morizane C, Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Kagami Y, Ikeda H. Chemotherapy for locally advanced pancreatic carcinoma in elderly patients. *Oncology* (in press).
105. Yonemori K, Ueno H, Okusaka T, Tamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. *Clin Cancer Res* (in press).

### Pain Medicine and Palliative Care Division

106. Shimoyama N, Shimoyama M. An antisense oligonucleotide to the N-Methyl-D-Aspartate (NMDA) subunit, NMDAR1, attenuates NMDA-induced nociception, hyperalgesia and morphine tolerance. *J Pharmacol Exp Ther* (in press)
107. Shimoyama M, Shimoyama N. Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer pain. *Pain* (in press)

### Pediatric Oncology Division

108. Makimoto A. Results of treatment of retinoblastoma that has infiltrated the optic nerve, is recurrent, or has metastasized outside the eyeball. *Int J Clin Oncol* 2004; 9: 7-12.
109. Matsubara H, Makimoto A, Higa T, Kawamoto H, Takayama J, Ohira M. High dose chemotherapy for metastatic retinoblastoma. *Bone Marrow Transplant* (in press)

### Psychiatry Division

110. Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y. Suicidality in terminally ill Japanese patients with cancer; prevalence, patient perceptions, contributing factors, and longitudinal changes. *Cancer*. 2004; 100: 183-191.
111. Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y. Major depression adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients; associated and predictive factors. *J Clin Oncol*. 2004; 22: 1957-1965.
112. Akechi T, Sakuma K, Okamura M, Akizuki N, Oba A, Nakano T, Uchitomi Y. Post traumatic symptoms experienced by a nurse after a patient suicide. *Jpn J Gen Hosp Psychiatry*. 2004; 16: 49-54.

113. Akizuki N, Yamawaki S, Akechi T, Nakano T, Uchitomi Y. Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. *J Pain Symptom Manage*.(in press)
114. Inagaki M, Matsuoka Y, Sugahara Y, Nakano T, Akechi T, Fujimori M, Imoto S, Murakami K, Uchitomi Y. Lack of association between hippocampal volume and a first major depressive episode after cancer diagnosis in breast cancer survivors. *Am J Psychiatry*.(in press)
115. Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, Nakano T, Nakashima N, Shima Y, JaeJoon S, Fujimori M, Uchitomi Y. Late referrals to specialized palliative care service in Japan. *J Clin Oncol*.(in press)
116. Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, Nakano T, Nakashima N, Shima Y, Matsubara T, Fujimori M, Uchitomi Y. Communication about the ending of anticancer treatment and transition to palliative care. *Ann Oncol*.(in press)

### Thoracic Oncology Division

117. Ohe Y, Niho S, Kakinuma R, Kubota K, Ohmatsu H, Goto K, Nokihara H, Kunitoh H, Saijo N, Aono H, Watanabe K, Tango M, Yokoyama A, Nishiwaki Y. A phase II study of cisplatin and docetaxel administered as 3 consecutive weekly infusions for advanced non-small cell lung cancer in elderly patients. *Ann Oncol* 2004; 15: 45-50.
118. Ohe Y. Chemoradiotherapy for lung cancer: current status and perspectives. *Int J Clin Oncol* 2004; 9: 435-443.
119. Sekine I, Nokihara H, Horiike A, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. *Br J Cancer* 2004; 90: 1125-1128.
120. Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. *Cancer Treat Rev* 2004; 30: 359-368.
121. Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M, Saijo N. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. *Cancer Sci* 2004; 95: 691-695.
122. Sekine I, Saijo N. Cancer Chemotherapy ? Overview on the Clinical Impact of Polymorphisms in Metabolizing Enzymes. In: Fuchs, Jurgen; Podda, M.(eds.) *Encyclopedia of Medical Genomics and Proteomics*. Marcel Dekker, Inc., New York, 2004
123. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. *Lung Cancer* 2004; 45: 93-104.
124. Niho S, Ohe Y, Goto K, Ohmatsu H, Matsumoto T, Kubota K, Kakinuma R, Nishiwaki Y. Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. *Jpn J Clin Oncol* 2004; 34: 69-73.

125. Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, Saijo N, Hanada K, Ogata H. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? *J Clin Oncol* 2004; 22: 2901-2908.
126. Goto K, Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Niho S, Kodama T, Shinkai T, Tamura T, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Yoshida K, Sugiura T, Matsui K, Saijo N. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. *Br J Cancer* 2004; 94: 659-665.
127. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Kamataki T. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. *Carcinogenesis* 2004; 25: 2451-2458
128. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H. Phase III randomized trial of docetaxel-cisplatin versus vindesine-cisplatin with stage IV non-small-cell lung cancer. *J Clin Oncol* 2004; 22: 254-261.
129. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. *Cancer Res* 2004; 64: 9101-9104.
130. Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. *Cancer Sci* 2004; 95: 984-989.
131. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. *Int J Cancer* 2004; 108: 464-472.
132. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N, Fukuoka M, Ariyoshi Y. Phase I-II Study of Amrubicin and Cisplatin in Previously Untreated Patients with Extensive-Stage Small-Cell Lung Cancer. *Ann Oncol* (in press)
133. Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, Ohe Y, Kodama T, Shimizu M, Nishio K, Ishizuka N, Saijo N. Randomized Pharmacokinetic and Pharmacodynamic Study of Docetaxel: Dosing Based on Body-Surface Area Compared With Individualized Dosing Based on Cytochrome P450 Activity Estimated Using a Urinary Metabolite of Exogenous Cortisol. *J Clin Oncol* (in press)
134. Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Watanabe S, Suzuki K, Asamura H, Tsuchiya R. Immunohistochemical KIT expression in thymic epithelial tumors. *Chest*, (in press)
135. Sakiyama T, Kohno T, Mimaki S, Ohta T, Yanagitani N, Sobue T, Kunitoh H, Saito R, Shimizu K, Hiramata C, Kimura J, Maeno G, Hirose H, Eguchi T, Saito D, Ohki M, Yokota J. Association of amino acid substitution polymorphisms in DNA repair genes, TP53, POLI, REV1 and LIG4, with lung cancer risk. *Int J Cancer* (in press)

### **Radiation Oncology Division**

136. Ikeda, H. Special report: Non-invasive management of invasive bladder cancer: Lectures by Professor William U. Shipley. *Jpn J Clin Oncol* 2003; 33: 592-594.
137. Shibamoto Y, Tsuchida E, Seki K, Oya N, Hasegawa M, Toda Y, Takemoto M, Sumi M, Hiratsuka J, Oguchi M, Hosono M, Yasuda S, Sougawa M, Kakutoh Y, Hayabuchi N. Primary central nervous system lymphoma in Japan 1995-1999: changes from the preceding 10 years. *J Cancer Res Clin Oncol*. 2004; 130: 351-356.
138. Nakamura K, Teshima T, Takahashi Y, Imai A, Koizumi M, Mitsuhashi N, Shioyama Y, Inoue T; Japanese PCS Working Subgroup of Prostate Cancer. Radiotherapy for localized hormone-refractory prostate cancer in Japan. *Anticancer Res*. 2004; 24: 3141-5.

### **Breast Surgery Division**

139. Akashi-Tanaka S, Fukutomi T, Sato N, Iwamoto E, Watanabe T, Katsumata N, Ando M, Miyakawa K, Nanasawa T, Hasegawa T. The use of contrast-enhanced computed tomography prior to neoadjuvant chemotherapy to identify patients likely to be treated safely with breast conserving surgery. *Ann Surg* 2004; 239(2): 238-243
140. Kinoshita T, Fukutomi T, Iwamoto E, and Akashi-Tanaka S, Prognosis of breast cancer patients with family history classified according to the menopausal status. *Breast J* 2004; 10: 218-222.
141. Kinoshita T, Fukutomi T and Kubouchi K, MR Imaging of benign phyllodes tumor of the breast. *Breast J* 2004; 3: 232-610
142. Takasugi M, Iwamoto E, Akashi-Tanaka S, Kinoshita T, Fukutomi T and Kubouchi K. General aspects and specific issues of informed consent on Breast Cancer Treatments. *Breast Cancer* 2005; 12: 439-44
143. Kinoshita T, Fukutomi T, Iwamoto E, Takasugi M, Akashi-T S and Hasegawa T. Intracystic papillary carcinoma of the breast in a male patient diagnosed by core needle biopsy. *The Breast* (in press)

### **Colorectal Surgery Division**

144. Akasu T, Iinuma G, Fujita T, Muramatsu Y, Tateishi U, Miyakawa K, Murakami T, Moriyama N. Thin-section MRI with a phased-array coil for preoperative evaluation of pelvic anatomy and tumor extent in patients with rectal cancer. *Am J Roentgenol* 2005; 184: 531-538.
145. Kubota K, Akasu T, Fujita S, Sugihara K, Moriya Y, Yamamoto S. Clinical and pathological prognostic indicators with colorectal mucinous carcinomas. *Hepatogastroenterology* 2004; 51: 142-146.
146. Moriya Y, Akasu T, Fujita S, Yamamoto S. Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. *Dis Colon Rectum* 2004; 47: 2047-2053.
147. Miyakura Y, Sugano K, Akasu T, Yoshida T, Maekawa M, Saitoh S, Sasaki H, Nomizu T, Konishi F, Fujita S, Moriya Y, Nagai H. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. *Clin Gastroenterol Hepatol* 2004; 2: 147-156.

148. Yamamoto S, Fujita S, Akasu T, Moriya Y. A comparison of the complication rates between laparoscopic colectomy and laparoscopic low anterior resection. *Surgical Endoscopy* 2004; 18: 1447-1451.
149. Yamamoto S, Akasu T, Fujita S, Moriya Y. Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: Is follow-up by CEA justified? *Hepatogastroenterology* (in press)
150. Moriya Y, Akasu T, Fujita S, Yamamoto S. Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer. *Surg Oncol Clin N Am* (in press)

### **Dermatology Division**

151. Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Yamaguchi K. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. *Anticancer Res* 2004; 24: 571-578.
152. Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: Immunohistochemical analysis of 115 cases. *Cancer*, (in press)
153. Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A. Syringoid eccrine carcinoma with apparently aggressive transformation: case report and review of the literature. *Int J Dermatol*, (in press)
154. Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Muir - Torre Syndrome with intriguing squamous lesions: case report and review of the literature. *Am J Dermatol*, (in press)

### **Esophageal Surgery Division**

155. Igaki H, Tachimori Y, Kato H. Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. *Ann Surg* 2004; 239: 483-490.

### **Gastric Surgery Division**

156. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group Study 9501. *J Clin Oncol* 2004; 22: 2767-2773
157. Katai H, Sasako M, Sano T, Fukagawa T. Gastric cancer surgery in the elderly without operative mortality. *Surg Oncol* 2004; 13: 235-8
158. Sasako M. Role of surgery in multidisciplinary treatment for solid cancers. *Int J Clin Oncol* 2004; 9: 346-351
159. Sayegh ME, Sano T, Dexter S, Katai H, Fukagawa T, Sasako M. TNM and Japanese staging systems for gastric cancer: how do they coexist? *Gastric Cancer* 2004; 7: 140-8
160. Whiting J, Sano T, Sasako M, Ajani JA. Report of the seventeenth international symposium of the Foundation for Promotion of Cancer Research: recent advances in gastric cancer. *Jpn J Clin Oncol* 2004; 34: 481-8

161. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, Kitano S, Hirohashi S. Increased DNA Methyltransferase 1(DNMT1) Protein Expression Correlates Significantly with Poorer Tumor Differentiation and Frequent DNA Hypermethylation of Multiple CpG Islands in Gastric Cancers. *Am J Pathol* 2004; 164: 689-699, 2004
162. Mori K, Aoyagi K, Ueda T, Danjoh I, Tsubosa Y, Yanagihara K, Matsuno Y, Sasako M, Sakamoto H, Mafune K, Kaminishi M, Yoshida T, Terada M and Sasaki H: Highly specific marker genes for detecting minimal gastric cancer cells in cytology negative peritoneal washings. *Biochemical and Biophysical Research Communications*, 2004; 313: 931-937
163. Ushijima T, Sasako M. Focus on gastric cancer. *Cancer Cell* 2004; 5: 121-125
164. Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, Kojima H, Hiratsuka M, Arai K, Sairenji M, Fukushima N, Kimura H, Nakajima T. Feasibility study of adjuvant chemotherapy with S-1(TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. *Gastric Cancer* 2004; 7: 104-109
165. Hartgrink HH, van de Velde CJH, Putter H, Bonenkamp JJ, Kranenbarg EK, Songun I, Welvaart K, va Krieken JHJM, Meijer S, Plukker JTM, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJB, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extend Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial. *J Clin Oncol* 2004; 22: 2069-2077
166. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, Scaglione D, Andreone D, Ponti A, Calvo F. Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomized surgical trial. *Eur J Surg Oncol* 2004; 30: 303-308
167. Aoki M, Yamamoto K, Noshiro H, Sakai K, Yokota J, Kohno T, Tokino T, Ishida S, Ohyama S, Ninomiya I, Uesaka K, Kitajima M, Shimada S, Matsuno S, Yano M, Hiratsuka M, Sugimura H, Itoh F, Minamoto T, Maehara Y, Takenoshita S, Aikou T, Katai H, Yoshimura K, Takahashi T, Akagi K, Sairenji M, Yamamura Y, Sasazuki T. A full genome scan for gastric cancer. *J Med Genet* (in press)
168. Saka M, Mudan SS, Katai H, Sano T, Sasako M, Maruyama K. Pancreaticoduodenectomy for advanced gastric cancer. *Gastric Cancer* (in press)
169. Katai H, Sano T, Sasako M, Fukagawa T, Saka M. Update on surgery of gastric cancer: new procedures versus standard technique. *Dig Dis* (in press)
170. Kubo T, Sano T, Fukagawa T, Katai H, Sasako M. Increasing body mass index in Japanese patients with gastric cancer. *Gastric Cancer* (in press)
171. Katai H, Yoshimura K, Fukagawa T, Sano T, Sasako. Risk factors for pancreas related abscess after total gastrectomy. *Gastric Cancer* (in press)

### Gynecology Division

172. Onda T, Katsumata N, Tsunematsu R, Yasugi T, Musika M, Yamamoto K, Fujii T, Hirakawa T, Kamura T, Saito T, and Yoshikawa H.: Cisplatin, Paclitaxel and escalating doses of Doxorubicin (TAP) in advanced ovarian cancer: a phase I trial.: *Jpn J Clin Oncol*: 2004; 34: 540-546.

173. Sawada M, Kimata Y, Kasamatsu T, Onda, Yamada T, Tsunematsu R.: Versatile lotus petal flap for vulvoperineal reconstruction after gynecological ablative surgery.: *Gynecol Oncol*: 2004; 95: 330-335.

### Hepatobiliary and Pancreatic Surgery Division

174. Shimada K, Kosuge T, Yamamoto J, Yamasaki S, Sakamoto M. Successful outcome after resection of pancreatic cancer with a solitary hepatic metastasis. *Hepatogastroenterol* 2004; 51: 603-5.
175. Sakamoto Y, Yamamoto J, Kosuge T, Sugawara Y, Azekura K, Kokudo N, Yamaguchi Y, Muto T, Makuuchi M. Extended left hepatectomy severing all major hepatic veins with reconstruction of the right hepatic vein. *Surg Today* 2004; 34: 482-4.
176. Shimada K, Sano T, Sakamoto Y, Kosuge T. Safety and curativity of left hepatic trisectionectomy for hilar cholangiocarcinoma. *World J Surg* (in press)
177. Shimada K, Sano T, Sakamoto Y, Kosuge T. Safe management of the pancreatic remnant with prolamine duct occlusion after extended pancreaticoduodenectomy. *Hepatogastroenterol* (in press)
178. Ohta H, Sakamoto Y, Ojima H, Yamada Y, Hibi T, Takahashi Y, Sano T, Shimada K, Kosuge T. Spontaneous regression of hepatocellular carcinoma with complete necrosis ? case report. *Abdom Imaging* (in press)
179. Nara S, Sakamoto Y, Shimada K, Sano T, Kosuge T, Takahashi Y, Onoya H, Yamamoto J. Necessity of arterial restoration during pancreatoduodenectomy in patients with celiac axis stenosis ? our experiences of 7 cases. *World J Surg* (in press)
180. Sakamoto Y, Kosuge T, Shimada T, Sano T, Ojima H, Yamamoto J, Yamasaki S, Takayama T, Makuuchi M. Prognostic factors of surgical resection in middle and distal bile duct cancer -An analysis of 55 patients concerning the significance of ductal and excisional margins- Surgery (in press)

### Neurosurgery Division

181. Shibui S, JCOG-Brain Tumor Study Group. A randomized controlled trial on malignant brain tumors. The activities of Japan Clinical Oncology Group (JCOG)-Brain Tumor Study Group (BTSG). *Neurol med chirur* 2004; 44: 220-221.

### Ophthalmology Division

182. Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. *Int J Clin Oncol* 2004; 9: 1-6.
183. Sugano K, Yoshida T, Izumi H, Umezawa S, Ushiyama M, Ichikawa A, Hidaka A, Murakami Y, Kodama T, Suzuki S, Kaneko A. Outpatient clinic for genetic counseling and gene testing of retinoblastoma. *Int J Clin Oncol* 2004; 9: 25-30.
184. Inomata M, Akihiro K. In vitro chemosensitivity assays of retinoblastoma cells. *Int J Clin Oncol* 2004; 9: 31-35.
185. Saito T, Endo M, Hiraga K, Kaneko A. Clinical trial of funduscopy under general anesthesia for pediatric outpatients with retinoblastoma. *Int J Clin Oncol* 2004; 9: 36-41.

186. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. *Int J Clin Oncol* 2004; 9: 69-73.
187. Akiyama K, Numaga J, Kagaya F, Takizawa Y, Suzuki S, Koseki N, Kato S, Kaburaki T, Kawashima H. Case of optic nerve involvement in metastasis of a gastrointestinal stromal tumor. *Jpn J Ophthalmol* 2004; 48: 166-168.

### Orthopedic Surgery Division

188. Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K, Beppu Y. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. *Cancer Letters* 2004; 204: 105-113.
189. Ida K, Kawaguchi S, Sato Y, Tsukahara T, Nabeta Y, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Kamiguchi K, Wada T, Nagoya S, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Ozaki T, Yoshikawa H, Yamashita T, Sato N. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A 2402 anchor substitute. *Journal of Immunology* 2004; 173: 1436-1443.

### Thoracic Surgery Division

190. Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Recent results of postoperative mortality for surgical resections in lung cancer. *Ann Thorac Surg* 2004; 78: 999-1002.
191. Suzuki K, Asamura H, Watanabe S, Tsuchiya R. Combined resection of superior vena cava for lung carcinoma: prognostic significance of patterns of superior vena cava invasion. *Ann Thorac Surg* 2004; 78: 1184-1189.
192. Sakurai H, Asamura H, Suzuki K, Watanabe S, Tsuchiya R. Management of primary malignant germ cell tumor of the mediastinum. *Jpn J Clin Oncol* 2004; 34: 386-392.
193. Sakurai H, Hasegawa T, Watanabe S, Suzuki K, Asamura H, Tsuchiya R. Inflammatory myofibroblastic tumor of the lung. *Eur J Cardiothorac Surg* 2004; 25: 155-159.
194. Sakurai H, Maeshima A, Watanabe S, Suzuki K, Tsuchiya R, Maeshima AM, Matsuno Y, Asamura H. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. *Am J Surg Pathol* 2004; 28: 198-206.
195. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Clinicopathologic features of peripheral squamous cell carcinoma of the lung. *Ann Thorac Surg* 2004; 78: 222-227.
196. Asamura H, Kamiya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K, Nagai K. Prognostic spectrum of pulmonary neuroendocrine carcinoma. *J Clin Oncol* (in press).
197. Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, Kato H. Phase II Trial of Postoperative Adjuvant Cisplatin and Etoposide in Patients with Completely Resected Stage I - IIIa Small Cell Lung Cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). *J Thorac Cardiovasc Surg* (in press).

### Urology Division

198. Takahashi A, Tsukamoto T, Tobisu K, Shinohara N, Sato K, Tomita Y, Komatsubara S, Nishizawa O, Igarashi T, Fujimoto H, Nakagawa H, Komatsu H, Sugimura Y, Ono Y, Kuroda M, Ogawa O, Hirao Y, Hayashi T, Tsushima T, Takehi Y, Arai Y, Ueda S, and Nakagawa M. Radical cystectomy for invasive bladder cancer: Results of multi-institutional pooled analysis. *Jpn J Clin Oncol* 2004; 34: 14-19.
199. Kitamura H, Fujimoto H, Tobisu K, Mizuguchi Y, Maeda T, Matsuoka N, Komiyama M, Nakagawa T, and Kakizoe T. Dynamic computerized tomography and color doppler ultrasound of renal parenchymal neoplasms: Correlations with histopathological findings. *Jpn J Clin Oncol* 2004; 34: 78-81.
200. Hirai K, Sasaki H, Yamamoto H, Sakamoto H, Kubota Y, Kakizoe T, Terada M, and Ochiya T. HST-1/FGF-4 protects male germ cells from apoptosis under heat-stress condition. *Experimental Cell Research* 2004; 294: 77-85.
201. Homma Y, Kondo Y, Kaneko M, Kitamura T, Nyou WT, Yanagisawa M, Yamamoto Y, and Kakizoe T. Promotion of carcinogenesis and oxidative stress by dietary cholesterol in rat prostate. *Carcinogenesis* 2004; 25: 1011-1014.